Journal article

Biomarker Glycoprotein Acetyls Associated With the Risk of a Wide Spectrum of Incident Diseases and Stratifies Mortality Risk in Angiography Patients

Johannes Kettunen, Scott C Ritchie, Olga Anufrieva, Leo-Pekka Lyytikainen, Jussi Hernesniemi, Pekka J Karhunen, Pekka Kuukasjarvi, Jari Laurikka, Mika Kahonen, Terho Lehtimaki, Aki S Havulinna, Veikko Salomaa, Satu Mannisto, Mika Ala-Korpela, Markus Perola, Michael Inouye, Peter Wurtz



BACKGROUND: Integration of systems-level biomolecular information with electronic health records has led to recent interest in the glycoprotein acetyls (GlycA) biomarker-a serum- or plasma-derived nuclear magnetic resonance spectroscopy signal that represents the abundance of circulating glycated proteins. GlycA predicts risk of diverse outcomes, including cardiovascular disease, type 2 diabetes mellitus, and all-cause mortality; however, the underlying detailed associations of GlycA's morbidity and mortality risk are currently unknown. METHODS: We used 2 population-based cohorts totaling 11 861 adults from the Finnish general population to test for an association with 468 common incident ho..

View full abstract

University of Melbourne Researchers


Awarded by National Health and Medical Research Council (NHMRC)

Awarded by Australian Heart Foundation

Awarded by Academy of Finland

Awarded by Novo Nordisk Foundation

Awarded by Tampere University Hospital

Awarded by EU Horizon 2020

Awarded by UK Medical Research Council

Funding Acknowledgements

This study was supported by funding from National Health and Medical Research Council (NHMRC) grant APP1062227 and by the Victorian Government's Operational Infrastructure Support program. Dr Inouye was supported by an NHMRC and Australian Heart Foundation Career Development Fellowship (No. 1061435). Drs Kettunen and Wurtz were funded by the Academy of Finland (grant No. 297338 and 307247, 312476, and 312477) and Novo Nordisk Foundation (NNF17OC0026062 and 15998). ANGES (Angiography and Genes Study) has been financially supported by the Competitive Research Funding of the Tampere University Hospital (grants 9M048 and 9N035), Academy of Finland: grant 286284 (for Dr Lehtimaki), the Finnish Cultural Foundation, the Finnish Foundation for Cardiovascular Research, the Emil Aaltonen Foundation, Finland, the Tampere Tuberculosis Foundation, and EU Horizon 2020 (grant 755320 for TAXINOMISIS). Dr Salomaa was supported by the Finnish Foundation for Cardiovascular Research. Dr Ala-Korpela was supported by the Sigrid Juselius Foundation. He works in a unit that is supported by the University of Bristol and UK Medical Research Council (MC_UU_12013/1).